바이오텍네(TECH) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

TECH

Bio-Techne Corp

7월 27일 3:53 PM ET (한국 7/28 04:53)

$71.60

-0.17 ▼ -0.24%

바이오텍네(TECH) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$11.2B

미드캡

P/E

102.8

고평가 구간

배당수익률

0.45%

52주 위치

98%

저점 +66% · 고점 -1%

애널리스트

보유

Fundamental health

vs. Biotechnology 대형주

수익성

Top 63%

성장

Top 77%

밸류에이션

Top 35%

재무 안정

Top 53%

💰 Is this stock pricier than usual right now?

Compared to this company's own recent 5년 (not other companies).

Very cheap

Cheap

Typical

Pricey

Very pricey

Simply put — what you pay today to own $1 of this company's yearly earnings is 102원. Over the past 5년, it usually traded around 66원. On the pricier side versus its own history.

Pricy doesn't mean bad — it means expectations are already baked in.

Index ⓘ	S&P 500	P/E ⓘ	102.84	EPS (ttm) ⓘ	0.7	Insider Own ⓘ	0.41%	Shs Outstand ⓘ	156.5M	Perf Week ⓘ	-0.72%
Market Cap ⓘ	11.21B	Forward P/E ⓘ	34.86	EPS next Y ⓘ	6.77%	Insider Trans ⓘ	-1.32%	Shs Float ⓘ	155.9M	Perf Month ⓘ	21.61%
Enterprise Value ⓘ	11.29B	PEG ⓘ	5.38	EPS next Q ⓘ	0.52	Inst Own ⓘ	115.09%	Short Float ⓘ	10.21%	Perf Quarter ⓘ	37.16%
Income ⓘ	0.11B	P/S ⓘ	9.26	EPS this Y ⓘ	0.18%	Inst Trans ⓘ	4.31%	Short Ratio ⓘ	3.32	Perf Half Y ⓘ	2.8%
Sales ⓘ	1.21B	P/B ⓘ	5.37	EPS next 5Y ⓘ	6.48%	ROA ⓘ	4.22%	Short Interest ⓘ	15.92M	Perf YTD ⓘ	21.75%
Book/sh ⓘ	13.32	P/C ⓘ	53.43	EPS past 3/5Y ⓘ	-34.8% -20.58%	ROE ⓘ	5.34%	52W High ⓘ	-0.78% ($72.16)	Perf Year ⓘ	22.46%
Cash/sh ⓘ	1.34	P/FCF ⓘ	41.58	Sales past 3/5Y ⓘ	3.33% 10.55%	ROIC ⓘ	4.64%	52W Low ⓘ	65.76% ($43.19)	Perf 3Y ⓘ	-18.55%
Dividend Est. ⓘ	$0.32 (0.45%)	EV/EBITDA ⓘ	30.61	EPS Y/Y TTM ⓘ	-15.73%	Gross Margin ⓘ	66.4%	Volatility(W/M) ⓘ	0.58% 0.86%	Perf 5Y ⓘ	-39.63%
Dividend TTM ⓘ	0.32	EV/Sales ⓘ	9.33	Sales Y/Y TTM ⓘ	0.17%	Oper. Margin ⓘ	22.18%	ATR (14) ⓘ	1.02	Perf 10Y ⓘ	158.6%
Dividend Ex-Date ⓘ	2026/5/18	Quick Ratio ⓘ	3.18	EPS Q/Q ⓘ	128.15%	Profit Margin ⓘ	9.05%	RSI (14) ⓘ	73.22	Recom ⓘ	2.67
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	4.49	Sales Q/Q ⓘ	-1.51%	SMA20 ⓘ	0.44% ($71.29)	Beta ⓘ	1.27	Target Price ⓘ	$70.33
Payout ⓘ	69.67%	Debt/Eq ⓘ	0.14	Earnings ⓘ	2026/5/6	SMA50 ⓘ	20.13% ($59.6)	Rel Volume ⓘ	0.43	Prev Close ⓘ	$71.77
Employees ⓘ	3100	LT Debt/Eq ⓘ	0.13	EPS/Sales Surpr. ⓘ	-0.79% -1.48%	SMA200 ⓘ	20.7% ($59.32)	Avg Volume(3M) ⓘ	4.79M	Price ⓘ	$71.6
IPO ⓘ	1989/2/9	Option/Short ⓘ	Yes/Yes			Trades ⓘ	17103	Volume ⓘ	2,065,538	Change ⓘ	-0.24%

Quarterly earnings trend SEC filings · USD

24.6*

24.9

24.12

25.3

25.6*

25.9

25.12

26.3

Revenue Net income 최근 분기: 매출 $311M (YoY -2%) · 순이익 $51M (YoY +126%)

* Q4 figures are derived from the annual filing (10-K) · loss-making quarters are underlined in red

📊 Bio-Techne Corp (TECH) Investment Analysis

What kind of company is Bio-Techne Corp?

바이오텍네(TECH)

Healthcare · Biotechnology

#884 by Market Cap — Mid-Cap

🔬 A healthcare tools company that supplies high-purity proteins, antibodies, reagents, and analytical instruments used in life sciences research and clinical diagnostics. It covers recombinant proteins, antibodies, immunoassay products, protein analysis platforms, and diagnostic products, making it a life sciences tools name whose earnings are tied to research and development and diagnostics demand.

Learn more about Bio-Techne Corp →

Market Cap

$11.2B

Approx. KRW 15.4 trillion

⚖️ 4% of Samsung Electronics

Market Cap Rank884

Employees3,100people

IPO1989/02/09

Current Price$71.60 ≈ 98,092원

📌 S&P 500 · NASD · USA

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🎯 Ex-div 2026년 5월 18일 (월) 주당 $0.08

🔔 Earnings release 2026년 5월 6일 (수) · 장 시작 전 EPS -0.8% 매출 -1.5%

🎯 Ex-div 2026년 2월 13일 (금) 주당 $0.08

🔔 Earnings release 2026년 2월 4일 (수) · 장 시작 전 EPS +6.0% 매출 +1.9%

Is it profitable?

Financial health solid

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

22.2%

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology 대형주 Median 14.7% · Top 35%

💡 일반적으로 10% 이상이면 양호, 20% 이상이면 우수

Net Margin

Share of revenue left after taxes and interest are paid

9.1%

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology 대형주 Median 8.6% · Top 49%

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

66.4%

✓ 매우 부진

My positionBottom 5%

Low range Average High range

Biotechnology 대형주 Median 86.4% · Bottom tier

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

5.3%

✓ 평균

My positionMid-range

Low range Average High range

Healthcare 대형주 Median 11.9% · Bottom 29%

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

4.2%

✓ 평균

My positionMid-range

Low range Average High range

Healthcare 대형주 Median 5.1% · Bottom 42%

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

4.6%

✓ 평균

My positionMid-range

Low range Average High range

Healthcare 대형주 Median 7.4% · Bottom 36%

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

0.14

✓ Healthy debt

My positionMid-range

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

4.49

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

3.18

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$70.33

현재가 대비 -1.8%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

34.86배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

PEG (성장 반영 밸류)

5.38

고평가

💡 PEG > 2 — 성장 대비 비싼 편

내년 EPS 예상 성장률

+6.8%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

5년 EPS 예상 연평균

+6.5%

💡 장기 성장 전망. 15% 이상이면 고성장 기업

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Slight tendency to beat estimates

예상 상회

예상 부합

예상 하회

50%

상회 비율

+2.5%

평균 서프라이즈

2026.05.06

부합

실적 $0.53 · 예상 $0.53 -0.8%

2026.02.04

상회

실적 $0.46 · 예상 $0.43 +5.8%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Growth Concerns

Growth is lagging the industry average

Declining Growth EPS or revenue is declining — check for structural issues or economic sensitivity

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+0.2%

양호

My positionMid-range

Low range Average High range

미분류 대형주 Median 0.2% · Around average

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

+6.8%

부진

My positionBottom 25%

Low range Average High range

미분류 대형주 Median 13.0% · Bottom 25%

5-Year EPS CAGR Outlook

Projected average annual EPS growth over the next 5 years

+6.5%

매우 부진

My positionBottom 5%

Low range Average High range

Biotechnology 대형주 Median 22.6% · Bottom tier

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

-34.8%

부진

My positionBottom 25%

Low range Average High range

미분류 대형주 Median 10.1% · Bottom 15%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

-20.6%

부진

My positionBottom 25%

Low range Average High range

미분류 대형주 Median -3.1% · Bottom 24%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+10.6%

양호

My positionMid-range

Low range Average High range

미분류 대형주 Median 10.6% · Around average

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

-1.5%

매우 부진

My positionBottom 5%

Low range Average High range

미분류 대형주 Median 18.7% · Bottom tier

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Long-term weakness — -108%p below the market

TECH -39.6% · S&P 500 +68.0%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

-107.6%p

Significantly behind the market

vs Health Care (XLV)

-63.3%p

Significantly behind the sector average

1-year basis

vs S&P 500

+6.0%p

slightly ahead of the market

vs Health Care (XLV)

+2.7%p

roughly in line with the sector average

Rank among peers

5-year return Lowest among peers Based on 24 peers

1-year return Lower-Mid (lower 35%) Based on 24 peers

Current position within 52-week range

Low (-65.8%p) High (-0.8%p)

Current price is 65.8% above the 52-week low and 0.8% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-36.9%

Annualized volatility

58.0%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟡

Current diagnosis · 2026-07-24

Squeeze — volatility contraction, breakout imminent

Band width narrowed to 2.3%. Big move may be near. Above the Ichimoku cloud (bullish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-24

Neutral zone — weak trend

MACD 3.205 · Signal 3.845 · Hist -0.641. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

⚠️

Current diagnosis · 2026-07-24

Overbought zone — short-term pullback possible

RSI 73.2 (above 70). Buying pressure is excessive, and profit-taking may emerge. Stoch %K is also 68.1.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

In line with the industry average

Cheap on Vs. Assets·Vs. Sales, Pricey on Vs. Earnings, In line with peers on Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Pricey

🏢 Vs. Assets Cheap

🧾 Vs. Sales Cheap

💧 Vs. Cash Flow Mid-range

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

102.84x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Biotechnology median 15.34x · Bottom 1% — expensive within the industry

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

34.86x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology 대형주 median 22.38x · Around the industry average

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

5.37x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 대형주 median 7.26x · Around the industry average

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

9.26x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 대형주 median 9.45x · Around the industry average

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

30.61x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology median 22.58x · Around the industry average

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

41.58x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology median 18.43x · Around the industry average

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$70.33 vs. current price -1.8%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology

Who owns it?

Ownership flow shows some pressure

Insider modest net selling -1.3% · Institutional net buying +4.3% · Short interest elevated 10.2% · Short interest up +3.4pp over last 90d

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-1.3%

Insiders net selling

🏦 Institutions (funds & investors)

+4.3%

Institutions net buying

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 115.1%

Institution-led, stable structure

Healthcare 대형주 Median 91.9%

🧑‍💼 Insiders 0.4%

Low, common among large-caps

Healthcare 대형주 Median 0.8%

👤 Retail investors (estimated) 0.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

10.2%

Somewhat high

Healthcare 대형주 Median 3.6%

Past 90 days 📈 +3.4%p increase

Short interest days to cover

3.3 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 156.5M주

Float (tradable shares) 155.9M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

ETFs holding TECH

ETFs with the highest weightings · 10 total shown

GNOM

Global X Genomics & Biotechnology ETF

3.45%

$81M

FBT

First Trust NYSE Arca Biotechnology Index Fund

2.83%

$2.8B

PBE

Invesco Biotechnology & Genome ETF

2.73%

$283M

FMED

Fidelity Disruptive Medicine ETF

2.24%

$46M

RSPH

Invesco S&P 500 Equal Weight Health Care ETF

1.83%

$740M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

배당 지급 — 연 0.45%

배당보다 주가 성장에 가까운 비중

Dividend Yield

0.45%

Industry average 1.25%

Dividend Per Share

$0.32

Annualized

Payout Ratio

70%

Share of net income paid as dividends

5-Year Growth

0.0%

Annualized dividend growth

📅 지급월 2월 · 8월 · 11월

📊 총 이력 2008~2026 (70건)

연도별 배당 총액 추이

주당 배당금을 연 단위로 합산한 금액입니다. 막대가 우상향이면 매년 배당이 늘어나고 있다는 뜻입니다.

$0.32 +0.0%

2016

$0.32 +0.0%

2017

$0.32 +0.0%

2018

$0.32 +0.0%

2019

$0.32 +0.0%

2020

$0.32 +0.0%

2021

$0.32 +0.0%

2022

$0.32 +0.0%

2023

$0.32 +0.0%

2024

$0.32 +0.0%

2025

$X.XX 그 해 총 배당금 +X% 전년 대비 증가 -X% 감소

최근 배당 이력 총 70건

아래로 스크롤하면 과거 배당 이력을 볼 수 있습니다.

배당락일

주당 금액

지급일

당시 수익률

2026-02-13

$0.080

—

0.67%

2025-11-17

$0.080

—

0.55%

2025-08-18

$0.080

—

0.75%

2025-05-19

$0.080

—

0.65%

2025-02-14

$0.080

—

0.49%

2024-11-08

$0.080

—

0.53%

2024-08-19

$0.080

—

0.43%

2024-05-10

$0.080

—

0.49%

2024-02-09

$0.080

—

0.59%

2023-11-09

$0.080

—

0.70%

2023-08-17

$0.080

—

0.40%

2023-05-12

$0.080

—

0.49%

2023-02-10

$0.080

—

0.52%

2022-11-10

$0.080

—

0.47%

2022-08-12

$0.080

—

0.42%

2022-05-13

$0.080

—

0.44%

2022-02-10

$0.080

—

0.38%

2021-11-10

$0.080

—

0.32%

2021-08-13

$0.080

—

0.34%

2021-05-14

$0.080

—

0.32%

2021-02-11

$0.080

—

0.41%

2020-11-13

$0.080

—

0.42%

2020-08-17

$0.080

—

0.49%

2020-05-08

$0.080

—

0.59%

2020-02-13

$0.080

—

0.78%

2019-11-07

$0.080

—

0.79%

2019-08-15

$0.080

—

0.83%

2019-05-09

$0.080

—

0.79%

2019-02-14

$0.080

—

0.85%

2018-11-08

$0.080

—

0.93%

2018-08-16

$0.080

—

0.89%

2018-05-11

$0.080

—

1.06%

2018-02-15

$0.080

—

1.13%

2017-11-09

$0.080

—

1.28%

2017-08-16

$0.080

—

1.35%

2017-05-17

$0.080

—

1.17%

2017-02-15

$0.080

—

1.22%

2016-11-09

$0.080

—

1.54%

2016-08-25

$0.080

—

1.22%

2016-05-11

$0.080

—

1.58%

2016-02-10

$0.080

—

1.88%

2015-11-10

$0.080

—

1.41%

2015-08-13

$0.080

—

1.50%

2015-05-13

$0.080

—

1.28%

2015-02-11

$0.080

—

1.72%

2014-11-06

$0.080

—

1.71%

2014-08-19

$0.077

—

1.29%

2014-05-07

$0.077

—

1.67%

2014-02-12

$0.077

—

1.73%

2013-11-07

$0.077

—

1.42%

2013-08-14

$0.075

—

1.56%

2013-05-08

$0.075

—

2.19%

2013-02-13

$0.075

—

1.70%

2012-11-01

$0.075

—

2.04%

2012-08-08

$0.070

—

2.03%

2012-05-09

$0.070

—

2.01%

2012-02-08

$0.070

—

2.03%

2011-11-03

$0.070

—

1.95%

2011-08-10

$0.068

—

1.94%

2011-05-11

$0.068

—

1.68%

2011-02-09

$0.068

—

1.95%

2010-11-04

$0.068

—

2.17%

2010-08-12

$0.065

—

2.14%

2010-05-12

$0.065

—

1.62%

2010-02-10

$0.065

—

2.10%

2009-11-05

$0.065

—

1.57%

2009-08-13

$0.063

—

1.64%

2009-05-06

$0.063

—

1.29%

2009-02-11

$0.063

—

0.91%

2008-10-30

$0.063

—

0.37%

* "배당락일"은 배당받으려면 이 날 이전에 주식을 보유해야 하는 기준일입니다. 지급일·당시 수익률은 일부 종목에서 데이터가 없을 수 있습니다.

💰 내가 100만원 투자한다면

연간 배당금 (세후) 3,799원

5년 누적 (세후) 1.9만원

* 환율 1,370원, 세금 15% 반영. 5년 누적은 배당 성장률 연 0% 가정.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
TECH This Stock	$11.2B	102.8 ▼	5.4 ▼	5.34% ▲	0.45% ▼	-0.2%
LLY	$1.13T	43.0 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.9%
JNJ	$634.1B	30.5 ▼	7.5 ▼	25.74% ▲	2.04% ▲	+1.6%
ABBV	$458.2B	127.9 ▼	-	15221.82% ▲	2.65% ▲	+0.9%
UNH	$382.1B	27.1 ▼	3.9 ▼	12.49% ▲	2.15% ▲	-0.7%
MRK	$323.7B	36.9 ▼	7.1 ▼	18.97% ▲	2.49% ▲	+0.5%
Sector Avg	-	25.8	2.7	-48.83%	1.25%	-

Derivative ETFs for TECH

Leveraged, inverse, and covered call ETFs based on the underlying asset

24 derivative ETFs based on TECH (Leverage 8 · Inverse 8 · Covered Call 8)

These are based on the same underlying asset but carry a completely different risk and return profile. Please review the warning below first.

ℹ️ What is a Derivative ETF?

These are special ETFs that amplify, reverse, or monetize the price movement of an underlying ETF or security. Leveraged ETFs aim for 2–3× the daily move, Inverse ETFs target opposite-direction returns, and Covered Call ETFs generate monthly income from option premiums.

⚠️ Caution: Long-Term Holding

Leveraged and inverse ETFs track only the daily return. With high volatility, holding them for longer periods causes cumulative volatility decay—returns diverge further from the underlying index. They are meant for short-term trading.

📈 Leverage 8 ETFs that move 2-3x with TECH (high volatility)